What pharmacologic treatments are recommended to alleviate anxiety, stress‑related tension, sensory overload, or insomnia in highly sensitive individuals?

Medications for Highly Sensitive People

For highly sensitive individuals experiencing anxiety, stress-related tension, sensory overload, or insomnia, SSRIs (selective serotonin reuptake inhibitors) are the recommended first-line pharmacologic treatment for anxiety symptoms, while cognitive behavioral therapy for insomnia (CBT-I) should be prioritized before any sleep medication. 1

Pharmacologic Approach by Symptom Domain

For Anxiety and Stress-Related Tension

Start with SSRIs as first-line agents:

• Fluvoxamine, paroxetine, or escitalopram are specifically recommended 1
• Venlafaxine (an SNRI) is an alternative first-line option 1
• These recommendations come from the most recent 2023 Japanese guidelines for social anxiety disorder, which directly addresses anxiety and heightened sensitivity to social scrutiny 1

The evidence supporting SSRIs and SNRIs is consistent across anxiety disorder guidelines, though the strength of recommendation is "weak" with "low" certainty of evidence 1. This reflects the reality that while these medications work for many patients (60-85% efficacy), individual responses vary 2.

Avoid benzodiazepines as routine first-line treatment despite their common use in clinical practice. While they provide rapid symptom relief, guidelines consistently position them as secondary options due to dependence risks and lack of long-term efficacy data 3, 2, 4.

For Insomnia

CBT-I must be attempted first before considering any pharmacotherapy 3. This is a strong, evidence-based recommendation that prioritizes non-pharmacologic intervention.

If pharmacotherapy becomes necessary (when CBT-I is unavailable, ineffective, or as temporary adjunct):

• Low-dose doxepin (sedating antidepressant)
• Melatonin receptor agonists (ramelteon)
• Dual orexin receptor antagonists (suvorexant)
• Non-benzodiazepine BzRAs ("z-drugs") as short-term options 3, 5

The 2017 AASM guideline emphasizes that pharmacotherapy for insomnia should be considered mainly in patients unable to participate in CBT-I or who still have symptoms despite such treatment 3.

Critical Clinical Considerations

The anxiety-insomnia connection is bidirectional: Approximately 50% of individuals with anxiety experience sleep disturbances, and insufficient sleep can instigate or exacerbate anxiety 6. This creates a vicious cycle where heightened arousal during the day (characteristic of highly sensitive individuals) leads to sleep disruption, which further amplifies daytime anxiety and sensory overload 7, 8.

Timing matters: Recent evidence shows that individuals with insomnia symptoms experience elevated anxiety particularly in early morning (08:00), late afternoon/early evening (16:00-21:00), and late evening (~22:00) 7. This pattern of arousal dysregulation throughout the day is especially relevant for highly sensitive individuals.

Monotherapy versus combination: The 2023 guidelines explicitly state there is no recommendation for combining pharmacotherapy with psychotherapy for anxiety disorders 1. This doesn't mean combination is harmful, but rather that evidence doesn't demonstrate clear superiority over monotherapy.

Common Pitfalls to Avoid

1. Jumping to benzodiazepines: While tempting for rapid relief, these should be reserved for select cases due to tolerance, dependence, and rebound anxiety risks 3, 2

2. Using sleep medications without addressing underlying anxiety: The arousal dysregulation driving insomnia in highly sensitive individuals often requires treating the anxiety component first 6, 7, 8

3. Prescribing insomnia medications long-term without CBT-I: Pharmacotherapy should ideally be short-term and only after setting clear expectations about duration and goals 5

4. Ignoring the evidence hierarchy: Over-the-counter antihistamines and herbal agents lack demonstrated efficacy and carry safety concerns 3

Practical Treatment Algorithm

Step 1: Assess whether anxiety or insomnia is the primary complaint

• If anxiety predominates → Start SSRI (escitalopram, paroxetine, or fluvoxamine) 1
• If insomnia predominates → Refer for CBT-I first 3

Step 2: If both are present simultaneously

• Prioritize treating anxiety with SSRI, as this often improves sleep secondarily 2, 6
• Add CBT-I concurrently when available 3

Step 3: If insomnia persists despite anxiety treatment and CBT-I

• Consider adding low-dose doxepin, melatonin receptor agonist, or orexin antagonist 3, 5
• Set clear expectations for short-term use

Step 4: If inadequate response to first-line SSRI

• Switch to alternative SSRI or try venlafaxine (SNRI) 1, 2
• Consider novel agents under investigation (agomelatine shows promise for GAD) 4

The evidence base strongly supports starting with SSRIs for anxiety symptoms and CBT-I for insomnia, with pharmacologic sleep aids reserved for refractory cases or as temporary adjuncts 3, 1, 2, 5.